For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.

The closing price of Dianthus Therapeutics Inc (NASDAQ: DNTH) was $35.57 for the day, up 11.86% from the previous closing price of $31.8. In other words, the price has increased by $11.86 from its previous closing price. On the day, 2.04 million shares were traded. DNTH stock price reached its highest trading level at $36.57 during the session, while it also had its lowest trading level at $30.2.

Ratios:

Our analysis of DNTH’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 13.12 and its Current Ratio is at 13.12. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

On October 03, 2024, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $48.Oppenheimer initiated its Outperform rating on October 03, 2024, with a $48 target price.

Insider Transactions:

Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 09 ’25 when RYAN SAVITZ bought 20,000 shares for $31.80 per share.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DNTH now has a Market Capitalization of 1144937856 and an Enterprise Value of 888880448. For the stock, the TTM Price-to-Sale (P/S) ratio is 236.07 while its Price-to-Book (P/B) ratio in mrq is 3.78. Its current Enterprise Value per Revenue stands at 183.123 whereas that against EBITDA is -6.847.

Stock Price History:

The Beta on a monthly basis for DNTH is 1.45, which has changed by 0.29017043 over the last 52 weeks, in comparison to a change of 0.1725707 over the same period for the S&P500. Over the past 52 weeks, DNTH has reached a high of $32.80, while it has fallen to a 52-week low of $13.36. The 50-Day Moving Average of the stock is 63.46%, while the 200-Day Moving Average is calculated to be 68.00%.

Shares Statistics:

DNTH traded an average of 450.28K shares per day over the past three months and 1117710 shares per day over the past ten days. A total of 32.18M shares are outstanding, with a floating share count of 23.48M. Insiders hold about 27.05% of the company’s shares, while institutions hold 102.61% stake in the company. Shares short for DNTH as of 1755216000 were 5983909 with a Short Ratio of 13.29, compared to 1752537600 on 6104610. Therefore, it implies a Short% of Shares Outstanding of 5983909 and a Short% of Float of 22.75.

Earnings Estimates

Dianthus Therapeutics Inc (DNTH) is presently subject to a detailed evaluation by 6 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.87, with high estimates of -$0.74 and low estimates of -$1.09.

Analysts are recommending an EPS of between -$3.13 and -$3.83 for the fiscal current year, implying an average EPS of -$3.47. EPS for the following year is -$3.63, with 5.0 analysts recommending between -$3.05 and -$4.47.

Revenue Estimates

A total of 11 analysts have provided revenue estimates for DNTH’s current fiscal year. The highest revenue estimate was $5.03M, while the lowest revenue estimate was $1.36M, resulting in an average revenue estimate of $2.52M. In the same quarter a year ago, actual revenue was $6.24M